Clinical Trial

Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated January 21, 2026 (before its estimated January 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this phase III study is to learn if JKN2301 Dry Suspension works to treat uncomplicated influenza in Pediatric Participants aged 2 to 11 years.
Trial Details
NCT Number NCT07357051
Lead Sponsor Joincare Pharmaceutical Group Industry Co., Ltd
Conditions Respiratory Viral Infection
Enrollment 177 participants
Start Date 2025-11-07
Primary Completion 2026-01-31 (estimated)
Study Completion 2026-04-15 (estimated)
Updated on ClinicalTrials.gov 2026-01-21